AIM2 inflammasome regulated by the IFN-γ/JAK2/STAT1 pathway promotes activation and pyroptosis of monocytes in Coronary Artery Disease.
Zhao Y, Liang B, Sheng S, Wang C, Jin B, Zhang X, Cheng Y, Shen C, Zheng F., Free PMC Article

Overexpression of SOCS2 Inhibits EMT and M2 Macrophage Polarization in Cervical Cancer via IL-6/JAK2/STAT3 Pathway.
Li D, Huang Y, Wei M, Chen B, Lu Y.

Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.
Usart M, Stetka J, Luque Paz D, Hansen N, Kimmerlin Q, Almeida Fonseca T, Lock M, Kubovcakova L, Karjalainen R, Hao-Shen H, Börsch A, El Taher A, Schulz J, Leroux JC, Dirnhofer S, Skoda RC., Free PMC Article

Serine/Threonine kinase 16 phosphorylates STAT3 and confers a JAK2-Inhibition resistance phenotype in triple-negative breast cancer.
Zhu Z, Xiang Q, Li S, Chen C, Shi J.

Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia.
Haage TR, Charakopoulos E, Bhuria V, Baldauf CK, Korthals M, Handschuh J, Müller P, Li J, Harit K, Nishanth G, Frey S, Böttcher M, Fischer KD, Dudeck J, Dudeck A, Lipka DB, Schraven B, Green AR, Müller AJ, Mougiakakos D, Fischer T., Free PMC Article

Daucosterol regulates JAK2-STAT3 signaling pathway to promote megakaryocyte differentiation.
Zhang Z, Shang G, Lu Z, Hu J, Liu H, Lu T, Lu X.

A novel cancer-germline gene DAZL promotes progression and cisplatin resistance of non-small cell lung cancer by upregulating JAK2 and MCM8.
Zhou L, Le MNU, Du Y, Chen X, Jin M, Xiang H, Xia LE, Zhou J, He J, Ning Y.

KIAA0040 enhances glioma growth by controlling the JAK2/STAT3 signalling pathway.
He J, Xue K, Fan F, Li L, Rao X, Liu W, Nie C., Free PMC Article

Targeting C21orf58 is a Novel Treatment Strategy of Hepatocellular Carcinoma by Disrupting the Formation of JAK2/C21orf58/STAT3 Complex.
Jiang H, Wang Y, Wen D, Yu R, Esa SS, Lv K, Feng Q, Liu J, Li F, He L, Di X, Zhang S., Free PMC Article

Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms.
Collins TB, Laranjeira ABA, Kong T, Fulbright MC, Fisher DAC, Sturgeon CM, Batista LFZ, Oh ST.,

[leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) inhibits proliferation and promotes apoptosis of human HEL cells with JAK2 V617F mutation by blocking the JAK/STAT and PI3K/AKT signaling pathways].
Fan C, Zhang Y, Yang R, Wu X, Zhou J, Xue J.

Sciellin promotes the development and progression of thyroid cancer through the JAK2/STAT3 signaling pathway.
Guo H, Wang Z, Yin K, Ma R, Zhang Y, Yin F, Li H, Yin D.

JAK2V617F mutation is highly prevalent in patients with ischemic stroke: a case-control study.
Kristiansen MH, Kjær L, Skov V, Larsen MK, Ellervik C, Hasselbalch HC, Wienecke T., Free PMC Article

Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling.
Abraham BG, Haikarainen T, Vuorio J, Girych M, Virtanen AT, Kurttila A, Karathanasis C, Heilemann M, Sharma V, Vattulainen I, Silvennoinen O., Free PMC Article

Epithelial IL5RA promotes epithelial-mesenchymal transition in pulmonary fibrosis via Jak2/STAT3 cascade.
Chen S, Zhao T, Xie S, Wan X.

Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients.
Narlı Özdemir Z, İpek Y, Patır P, Ermiş G, Çiftçiler R, Özmen D, Baysal M, Gürsoy V, Yıldızhan E, Güven S, Ercan T, Elibol T, Mersin S, Genç E, Davulcu EA, Karakuş V, Erkut N, Güneş G, Diz Küçükkaya R, Eşkazan AE., Free PMC Article

Knockdown of liver cancer cell-secreted exosomal PSMA5 controls macrophage polarization to restrain cancer progression by blocking JAK2/STAT3 signaling.
Xie S, Li X, Yan J, Yu H, Chen S, Chen K., Free PMC Article

[Comparison of Clinical Characteristics of JAK2, CALR and Tri-Negative Driving Mutant Type in Patients with Essential Thrombocythemia].
Li YM, Yang EP, Wang ZQ, Wang DH, Niu JC, Li YJ, Ming J, Sun MQ, Chen Z, Liu WY, Lyu Y, Hu XM.

Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche.
Flosdorf N, Böhnke J, de Toledo MAS, Lutterbach N, Lerma VG, Graßhoff M, Olschok K, Gupta S, Tharmapalan V, Schmitz S, Götz K, Schüler HM, Maurer A, Sontag S, Küstermann C, Seré K, Wagner W, Costa IG, Brümmendorf TH, Koschmieder S, Chatain N, Castilho M, Schneider RK, Zenke M., Free PMC Article

Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation.
Chai J, Choudhuri J, Wang Q, Fang Y, Shi Y, Kamel J, Shah N, Sica RA, Kornblum N, Konopleva M, Mantzaris I, Shastri A, Gritsman K, Verma A, Goldfinger M, Goel S, Wang Y, Tian X.

LCN2 Promotes Proliferation and Glycolysis by Activating the JAK2/STAT3 Signaling Pathway in Hepatocellular Carcinoma.
Han B, An Z, Gong T, Pu Y, Liu K.

Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy.
Chen P, Long J, Zhang J, Xie F, Wu W, Tian Z, Zhang S, Yu K., Free PMC Article

A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance.
Gorantla SP, Mueller TA, Albers-Leischner C, Rudelius M, von Bubnoff N, Duyster J., Free PMC Article

Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms.
Holl K, Chatain N, Krapp S, Baumeister J, Maié T, Schmitz S, Scheufen A, Brock N, Koschmieder S, Moreno-Andrés D., Free PMC Article

PCSK9 regulates myofibroblast transformation through the JAK2/STAT3 pathway to regulate fibrosis after myocardial infarction.
Bao H, Wang X, Zhou H, Zhou W, Liao F, Wei F, Yang S, Luo Z, Li W.